University of Limerick Institutional Repository

Long-term outcome data for patients with HER2-positive early-stage breast cancer treated with adjuvant trastuzumab: benefit outside clinical trial setting

DSpace Repository

Show simple item record

dc.contributor.author Quintyne, Keith Ian
dc.contributor.author Woulfe, Bernie
dc.contributor.author Coffey, Calvin J.
dc.contributor.author Gupta, Rajnish Kumar
dc.date.accessioned 2019-11-19T09:34:57Z
dc.date.available 2019-11-19T09:34:57Z
dc.date.issued 2018
dc.identifier.uri http://hdl.handle.net/10344/8242
dc.description peer-reviewed en_US
dc.description.abstract Adjuvant treatment options for HER2 positive Early-Stage Breast Cancer (EBC) have grown in recent years. The addition of adjuvant trastuzumab therapy for one-year to standard chemotherapy has been shown in several Randomized Controlled Trials (RCTs) to improve Disease-Free Survival (DFS) and Overall Survival (OS) in patients with high-risk HER2-positive EBC. This study aimed to review the long-term outcome data for patients with HER2-positive EBC who were treated with adjuvant trastuzumab therapy in a designated cancer centre. Methods: Data included all women diagnosed with HER2-positive EBC between 1st January 2001 and 31st January 2010 (N=147). Retrospective evaluation of healthcare records for clinical, demographic, and pathologic data was undertaken. Most had adjuvant trastuzumab following systemic chemotherapy (80/147; 54.4%). Kaplan-Meier estimates were used to evaluate whether one-year trastuzumab administration was associated with improved DFS and OS. Additionally, cohorts were generated by pathologic tumour size and lymph node involvement to stratify outcome measures (i.e. DFS and OS) by risk features. en_US
dc.language.iso eng en_US
dc.publisher MedDocs Publishers en_US
dc.relation.ispartofseries Annals of Breast Cancer;1, 1002
dc.subject breast cancer en_US
dc.subject HER2-positive en_US
dc.subject Disease-Free survival en_US
dc.title Long-term outcome data for patients with HER2-positive early-stage breast cancer treated with adjuvant trastuzumab: benefit outside clinical trial setting en_US
dc.type info:eu-repo/semantics/article en_US
dc.type.supercollection all_ul_research en_US
dc.type.supercollection ul_published_reviewed en_US
dc.rights.accessrights info:eu-repo/semantics/openAccess en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search ULIR


Browse

My Account

Statistics